In This Section

Research Funding Impact

Since 1993, the AACR has awarded more than $540 million in grants to fund meritorious research projects across the spectrum of cancer science, including basic, translational, and clinical research. See how the AACR grants program has contributed to the AACR's mission.

Loading...
<strong>Dr. Rosa Hwang shares the important contribution of the AACR-Bayer Innovation and Discovery Grant on her road to develop novel treatment strategies</strong>

Dr. Rosa Hwang shares the important contribution of the AACR-Bayer Innovation and Discovery Grant on her road to develop novel treatment strategies

The AACR-Bayer Innovation and Discovery Grants sought to uncover new treatment options for cancers with high unmet medical need and encourage translation of ideas from basic research into novel drugs. Surgical oncologist, Rosa Hwang, MD, received the grant in 2016, helping her pursue a new therapeutic target in pancreatic cancer.

Dr. Fariba Behbod shares how AACR grant support impacted her research on DCIS

Dr. Fariba Behbod shares how AACR grant support impacted her research on DCIS

AACR Special Conference “Rethinking DCIS: An Opportunity for Prevention” Plenary Session Speaker Fariba Behbod, Pharm D, PhD, received the AACR-Breast Cancer Research Foundation for Translational Breast Cancer Research award in 2014, when she was an Assistant Professor at the Kansas University Medical Center Research Institute. Now a Full Professor, she speaks on the impact of the AACR grant on her research and career.

Bosarge Family Foundation-Waun Ki Hong Scholar Identifies a Novel Target to Mitigate Chemobrain

Bosarge Family Foundation-Waun Ki Hong Scholar Identifies a Novel Target to Mitigate Chemobrain

Chemotherapy-induced cognitive impairment (CICI), also known as chemobrain, can affect up to 75% of patients during treatment. Recipient of the 2019 The Bosarge Family Foundation-Waun Ki Hong Scholar Award for Regenerative Cancer Medicine Alfredo Oliveros, PhD, and his colleagues showed that inhibiting adenosine A2A receptor signaling can prevent cisplatin-induced cognitive impairment.